MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance)
December 1, 2021
December 1, 2021
Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability
November 1, 2021
November 1, 2021
MedinCell announces participation in the Jefferies London Healthcare Conference 2021
October 25, 2021
October 25, 2021
MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021
October 21, 2021
October 21, 2021
MedinCell releases the results of its September 9, 2021 ordinary annual and extraordinary general meeting
September 10, 2021
September 10, 2021
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
September 1, 2021
September 1, 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
August 31, 2021
August 31, 2021
Participation terms in the MedinCell Combined General Meeting
August 4, 2021
August 4, 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report
July 28, 2021
July 28, 2021
MedinCell announces the initiation of coverage of its stock by ODDO-BHF
July 26, 2021
July 26, 2021
MedinCell announces fiscal year consolidated results April 2020 – March 2021
June 16, 2021
June 16, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
June 14, 2021
June 14, 2021
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
